Friends of Cancer Research’s Post

Curadev is thrilled to introduce CRD3874, a first-in-class allosteric #smallmolecule #STINGagonist, with distinct pharmacological properties that distinguish it from agents that bind to STING's cGAMP site. "CRD3874 is clearly unlike CDN-competitive STING agonists, since its distinct pharmacology and tolerability appear to be related to its allosteric binding mode. We are hopeful that the promising preclinical studies presented here will speak to the therapeutic potential of immune activation by CRD3874-SI in the context of advanced cancer in humans," said Monali Banerjee, VP R&D at #Curadev, who leads the STING programs. ➡️ Read the full announcement from Yahoo Finance:

Proud to have been able to contribute to this research. Another great article, assessing ADC and recombinant photo-activated therapeutic efficacy for light-accessible and light-inaccessible tumors. https://lnkd.in/dFwTibUM

𝐂𝐚𝐥𝐥𝐢𝐝𝐢𝐭𝐚𝐬 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐃𝐚𝐭𝐚 𝐟𝐨𝐫 𝐒𝐞𝐭𝐚𝐧𝐚𝐱𝐢𝐛 𝐢𝐧 𝐒𝐂𝐂𝐇𝐍 𝐓𝐫𝐢𝐚𝐥 Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) Calliditas Therapeutics announced positive data from the Phase 2 trial of setanaxib in combination with pembrolizumab for squamous cell carcinoma of the head and neck (SCCHN). The trial showed significant improvements in progression-free survival (PFS) and overall survival (OS), along with changes in tumor biology consistent with setanaxib's mechanism of action. The trial involved 55 patients with recurrent or metastatic SCCHN. Patients receiving pembrolizumab and setanaxib demonstrated significant improvements in key secondary endpoints compared to those receiving pembrolizumab and placebo. Transcriptomic analysis showed an increase in CD8+ T-cells in setanaxib-treated patients. "The results provide a strong basis for advancing setanaxib," said Professor Kevin Harrington. CEO Renée Aguiar-Lucander Renee Aguiar-Lucander expressed excitement about the positive clinical evidence supporting their NOX platform. CMO Richard Philipson Richard Philipson thanked the trial participants and investigators for their contributions. Calliditas is conducting additional trials with setanaxib, with readouts expected in Q3 and Q4 of 2024 and 1H 2025. An R&D day in Stockholm will provide further details. #CalliditasTherapeutics #Setanaxib #SCCHN #CancerResearch #Immunotherapy #ClinicalTrials #Biopharma #MedicalInnovation #NOXInhibitor #SurvivalImprovement

BioProcess International has published an insightful article featuring our CEO, Dr. Ofer Sharon, on the challenges of estimating #ICI suitability in #cancertreatment. 🧬 Ofer highlights the urgent need for a paradigm shift in how researchers and IVD developers approach #biomarkers for treatment suitability, especially in light of the limitations surrounding PD-1/PD-L1 as predictors of ICI success. 🧠 OncoHost is pioneering a new way to address this complexity by leveraging AI/ML to analyze #proteomic data from patient blood plasma. Our platform provides oncologists with accurate, actionable insights into tumor resistance, helping them make informed decisions about ICI-based therapies. Read the full article to learn more about our innovative approach and how it’s shaping the future of precision oncology! 🔗https://lnkd.in/dP6wq3Rm #PrecisionOncology #AI #CancerResearch #Proteomics #ICITherapy #Biotech

This is the first time EVER that an #IHC test has received tumor – agnostic #FDA approval. Huge congratulations to #AstraZeneca and #DaichiSankyo on yet another historic milestone. 👏👏 Hopefully, this is a harbinger of approvals to come as the pipeline for #ADC therapies is robust. With this unprecedented approval, we are likely to see an acceleration in the use of #PrecisionDiagnostics. The implications for patient care are enormous. Every patient with an advanced solid tumor malignancy will have the opportunity to be tested and potentially benefit from this highly innovative and efficacious therapy. Laboratories will need to come together to make testing readily available and democratize eqiutable patient access to #PrecisionOncology. Testing is available at #PathGroup. We have been working diligently to optimize testing here. #HER2 #cancerdiagnostics #precisionmedicine #Enhertu #GenomicEducation #GE

𝐈𝐃𝐄𝐀𝐘𝐀 𝐁𝐢𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞𝐬 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐈𝐧𝐭𝐞𝐫𝐢𝐦 𝐏𝐡𝐚𝐬𝐞 2 𝐃𝐚𝐭𝐚 𝐟𝐨𝐫 𝐃𝐚𝐫𝐨𝐯𝐚𝐬𝐞𝐫𝐭𝐢𝐛 𝐢𝐧 𝐍𝐞𝐨𝐚𝐝𝐣𝐮𝐯𝐚𝐧𝐭 𝐔𝐯𝐞𝐚𝐥 𝐌𝐞𝐥𝐚𝐧𝐨𝐦𝐚 IDEAYA Biosciences has announced positive interim Phase 2 clinical trial data for darovasertib in neoadjuvant uveal melanoma (UM) and a successful FDA Type C meeting on registrational trial design for regulatory approval. 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: • Approximately 49% of patients demonstrated greater than 30% tumor shrinkage. • ~61% eye preservation rate observed for enucleation patients. • Manageable adverse event profile with 11% grade 3 or higher AEs and 5% serious AE rate. 𝐀𝐛𝐨𝐮𝐭 𝐃𝐚𝐫𝐨𝐯𝐚𝐬𝐞𝐫𝐭𝐢𝐛: • Potent and selective protein kinase C (PKC) inhibitor. • Designed to address primary and metastatic uveal melanoma (UM). • Company-sponsored Phase 2 trial assessing darovasertib as neoadjuvant treatment prior to enucleation or radiation therapy, and as adjuvant therapy. • Investigator-sponsored trial (IST) also evaluating darovasertib for neoadjuvant UM. IDEAYA is committed to advancing darovasertib towards potential regulatory approval and improving outcomes for patients with uveal melanoma. #Darovasertib #UvealMelanoma #ClinicalTrials #Oncology

Usually if a patient has HNSCC and upto metastatic stage, that is hard enough for oncologist to deal with. Even more desperate if the patient is with PD-L1 level less than 1%, in which case anti-PD1 drugs are not meant to be beneficial. Then if that patient is not suitable to take chemotherapy, practically, out of option so far. However, things are about to change from now on, because of this small peptide, Eftilagimod Alpha, from Immutep!

In an impressive stride for precision medicine, Alterome Therapeutics, Inc has just unveiled compelling pre-clinical data for their lead AKT1 E17K inhibitor program. Dubbed ALTA-2618, this compound targets a specific mutation found across various aggressive cancers which gives some hope for those patients facing limited treatment avenues 💊🙌 During rigorous preclinical studies, this potential game-changer didn't just inhibit; it showcased remarkable tumor shrinkage, paired with oral bioavailability that's ideal for patient use. Later this year, Alterome will be gearing up for a pivotal phase: first-in-human clinical trials so let's watch this space as ALTA-2618 ventures from bench to bedside, potentially transforming many lives!✅📈 #PrecisionMedicine #CancerResearch #Oncology #AlteromeTherapeutics #ClinicalTrials #ClinicalResearch #MedicalInnovation #LifeScience #ElixirAssociates #StaffingPartner

🔬 #AACR24 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐚𝐭𝐚 & 𝐒𝐭𝐨𝐜𝐤 𝐌𝐨𝐯𝐞𝐬 📈 At this year's #cancer conference we saw not just pre-clinical, but also new clinical data… Here's a glimpse at some clinical readouts and how stocks reacted 👇  Get updates like this each week → https://lnkd.in/gGSgpiJM Kazia Therapeutics Limited (NASDAQ: KZIA) Readout details: Ph1 initial data of EVT801 Indication: Advanced Solid Tumors Results details: Safety data on first enrolled patients showed no safety alert which allows further dose escalation Elicio Therapeutics (NASDAQ: ELTX) Readout details: Updated Ph1 data from AMPLIFY-201 Indication: Pancreatic & Colorectal cancer Results details: The majority of ELI-002-treated patients tested had antigen spreading where induced T cells targeted additional patient-specific tumor mutations beyond mKRAS & observed to have durable mKRAS-specific T cell response with increased memory T cell phenotype. RAPT Therapeutics (NASDAQ: RAPT) Readout details: Ph2 data of tivumecirnon in combo w/ pembrolizumab Indication: Solid Tumors (NSCLC) Results details: Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status Purple Biotech (NASDAQ: PPBT) Readout details: Ph1/2 study data of NT219 in combo w/ cetuximab Indication: SCCHN Results details: Effectively suppress cancer stem cells (CSC) and promote resistance and tumor recurrence. -- 👋 I'm Dominic Vacchiano, Co-founder of BiopharmIQ by Amp. We provide biopharma data to help with your sales/BD activities. 📰 Each week we share clinical/regulatory/funding news in an easy-to-digest format. #biotech #biopharma #aacr24

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, announced the dosing of the first patient in its Phase 1, first-in-human clinical trial evaluating SOT201, a next-generation PD-1-targeting immunocytokine. The VICTORIA-01 study (NCT06163391) will evaluate the safety, tolerability and initial efficacy of SOT201 monotherapy for the treatment of advanced solid tumors. SOT201 is an antibody-cytokine fusion protein that could improve upon the efficacy of approved checkpoint inhibitors by combining PD-1 targeting with IL-15 immune stimulation in a single therapeutic construct.  #mabs https://lnkd.in/dtkU37Ju